Drugs Containing Excipient (Inactive Ingredient) EDETATE DISODIUM

Branded drugs containing EDETATE DISODIUM excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	EMEND	fosaprepitant dimeglumine	0006-3061	EDETATE DISODIUM
Merck Sharp & Dohme Corp	EMEND	fosaprepitant dimeglumine	0006-3884	EDETATE DISODIUM
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0923	EDETATE DISODIUM

Generic drugs containing EDETATE DISODIUM excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme LLC	fosaprepitant dimeglumine	0006-3061	EDETATE DISODIUM
Merck Sharp & Dohme Corp	fosaprepitant dimeglumine	0006-3884	EDETATE DISODIUM
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	pantoprazole sodium	0008-0923	EDETATE DISODIUM

Market Dynamics and Financial Trajectory for Edetate Disodium

Last updated: February 19, 2026

What Is Edetate Disodium?

Edetate disodium (EDTA disodium salt) is a chelating agent used primarily in pharmaceutical formulations to bind metal ions. It stabilizes formulations, enhances efficacy, and prevents metal-catalyzed oxidation. It also has applications in blood collection tubes, dialysis, and chelation therapy.

Market Size and Growth

The global market for EDTA disodium is estimated at approximately USD 455 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, reaching USD 675 million by 2030 (Research and Markets, 2022).

Key Market Drivers

• Pharmaceuticals and Biotech: Increasing demand for chelation therapy and intravenous formulations.
• Personal Care and Food Industry: Usage as a preservative stabilizer.
• Regulatory Approvals: Recognition by health authorities as safe within defined limits spurs adoption.
• Aging Population: Growing conditions requiring chelation and detoxification therapies.

Regional Outlook

Region	Market Share (2022)	CAGR (2023-2030)	Key Factors
North America	35%	4.2%	High pharmaceutical sector penetration
Europe	30%	4.7%	Stringent safety standards
Asia-Pacific	25%	5.2%	Rapid industrialization and R&D surge
Latin America	7%	3.8%	Emerging healthcare infrastructure
Middle East & Africa	3%	3.5%	Growing pharmaceutical manufacturing

Supply Chain and Key Players

The supply chain includes intermediates synthesis, shipping, and formulation manufacturing. Major suppliers include:

• BASF SE: Largest producer, globally integrated, supplies to pharma and industrial sectors.
• Tianjin University: Supplies semi-synthetic forms, focusing on cost competitiveness.
• Riedel-de Haën (Sigma-Aldrich/Merck): Provides high-purity EDTA disodium variants.

Market entry barriers encompass regulatory compliance, manufacturing costs, and purity standards.

Regulatory and Patent Landscape

Regulations

• US FDA: Recognized as safe within specified limits; no dedicated monograph but included in general excipient guidelines.
• EMA: Similar recognition in Europe, with batch testing standards.

Patent Trends

Existing patents cover formulations, manufacturing processes, and crystalline forms. No active patent expirations are anticipated before 2025, leaving limited generic competition initially. Future innovations may focus on eco-friendly synthesis and improved bioavailability.

Financial Trajectory Projections

The revenue trajectory mirrors market growth, driven by pharmaceutical demand and regulatory acceptance.

Year	Estimated Market Size (USD Million)	CAGR	Notes
2022	455	-	Baseline
2025	540	4.7%	Near-term growth influenced by pharma
2030	675	4.5%	Longer-term growth aligns with industry

Profit margins for producers are stable at approximately 12-15%, influenced by raw material costs, regulatory compliance, and R&D expenses.

Market Risks

• Regulatory Changes: Stricter safety evaluations could restrict usage.
• Raw Material Prices: Fluctuations in feedstock costs may pressure margins.
• Environmental Regulations: Stringent waste disposal and eco-friendly manufacturing may increase costs.

Opportunities

• New Indications: Expanding use in chelation therapy and blood detoxification.
• Formulation Innovations: Developing water-soluble or bioavailable formulations.
• Emerging Markets: Increasing penetration in Asia-Pacific and Latin America.

---

Key Takeaways

• The Edetate Disodium market is poised for steady growth, driven by pharmaceutical needs and regulatory acceptance.
• Asia-Pacific will see the highest CAGR, underpinned by industrialization and healthcare expansion.
• Supply chain dominance is concentrated among a few large multinationals, with BASF leading.
• Patent protections offer limited competition until 2025, favoring early movers.
• Regulatory environment remains generally favorable but demands compliance with safety standards.

---

FAQs

1. What are the primary applications of EDTA disodium in pharmaceuticals?
Used as a chelating agent in intravenous solutions, blood collection tubes, and chelation therapy to remove heavy metals.

2. How does regulation impact the market for EDTA disodium?
Regulatory approval with safety limits supports market stability. Changes could restrict usage or increase compliance costs.

3. What are the main raw material risks for producers?
Fluctuations in feedstock prices and environmental regulations on waste disposal can affect margins.

4. Are there significant patent barriers for new entrants?
Existing patents mainly cover manufacturing processes and formulations, expiring around 2025, allowing future generic competition.

5. Which regions present the most growth opportunity?
Asia-Pacific and Latin America offer significant potential due to expanding healthcare and pharmaceutical markets.

---

References

[1] Research and Markets. (2022). Edetate Disodium Market - Global Outlook & Forecast 2022-2030.